Compare KELYA & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | CERS |
|---|---|---|
| Founded | 1946 | 1991 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Professional Services | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.8M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | KELYA | CERS |
|---|---|---|
| Price | $8.72 | $1.69 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 403.2K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $20.00 |
| Revenue Next Year | $4.60 | $9.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $7.98 | $1.12 |
| 52 Week High | $14.94 | $2.96 |
| Indicator | KELYA | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 30.71 |
| Support Level | $8.42 | $1.37 |
| Resistance Level | $8.90 | $2.26 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 6.72 | 5.66 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.